Intuitive Surgical to Begin Direct Operations in India

M Neelam Kachhap
M Neelam Kachhap
· 3 min read
Intuitive Surgical begins operations in India

Intuitive Surgical, Inc., (Nasdaq:ISRG) recently announced that it has begun direct operations in India, following seven years of doing business in the country through a distributor, Vattikuti Technologies Pvt. Ltd.

Intuitive pioneered, and continues to be a global leader in, the field of robotic-assisted, minimally invasive surgery with the creation of its da Vinci surgical system more than two decades ago. Now on its fourth-generation system, the Silicon Valley-based company has seen more than five million robotic-assisted surgical procedures performed worldwide, and the da Vinci surgical system benefits explored in more than 15,000 peer-reviewed scientific publications to date.

“The adoption and advancement of robotic-assisted surgery has been enabled by critical contributions from health care professionals from India,” said Intuitive CEO Gary Guthart. “As Intuitive continues to grow to serve patients, surgeons, and hospitals in India, we look forward to deepening our support of, and work with, health care professionals in their pursuit of the clinical and economic benefits robotic-assisted surgery offers.”

In support of the company’s commitment to India, Intuitive also named Mandeep Singh Kumar as its general manager. Mandeep will direct and implement Intuitive’s in-country strategy and commercial operations. He has more than 20 years of global business experience in health care, pharmaceuticals, medical devices, and advertising. Most recently, Mandeep served as the chief commercial officer for GE Healthcare, India and South Asia. “It is a privilege to be part of Intuitive’s journey in India, and we are committed to working with surgeons across the country to bring the benefits of robotic-assisted surgery to their patients,” said Mandeep.

Intuitive’s sixth international office will be headquartered in Bengaluru, where employees in sales, marketing, field service engineering, and business operations will be based to support customers throughout the country. More than 65 da Vinci surgical systems are currently in use in India, with surgeons performing robotic-assisted procedures in urology, gynecology, thoracic, and general surgery.

“Our customers can expect a smooth transition and even deeper collaboration opportunities between Intuitive and India’s surgical community,” said Jeroen van Heesewijk, senior vice president of global distribution at Intuitive. “We look forward to welcoming our new colleagues to the Intuitive team, as well.” More than 60 former Vattikuti employees became a part of Intuitive India’s business.  Terms of the deal were not disclosed.

Intuitive Surgical, headquartered in Sunnyvale, Calif. is the pioneer in robotic-assisted, minimally invasive surgery. Intuitive develops, manufactures and markets the da Vinci surgical system. The Company’s mission is to make surgery more effective, less invasive and easier on surgeons, patients and their families. There are several models of the da Vinci surgical system. The da Vinci surgical systems are designed to help surgeons perform minimally invasive surgery. Da Vinci systems offer surgeons high-definition 3D vision, a magnified view, and robotic and computer assistance. They use specialized instrumentation, including a miniaturized surgical camera and wristed instruments (i.e., scissors, scalpels and forceps) that are designed to help with precise dissection and reconstruction deep inside the body.

 

Read Next

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management
Corporate
January 27, 2026

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management

Company to launch product after the expiry of semaglutide patent in India Sun Pharmaceutical Industries has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for chronic weight management in adults as an adjunct to […]
Article by: IMT News Desk
Lupin receives highest ESG rating from CDP for climate change and water security
Corporate
January 27, 2026

Lupin receives highest ESG rating from CDP for climate change and water security

The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency at the highest level Lupin has received the highest ‘A’ leadership rating from Climate Disclosure Project (CDP) for its exceptional accomplishments in Climate Change and Water Security. The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency […]
Article by: IMT News Desk
AstraZeneca Pharma India receives CDSCO approval for breast cancer drug
Corporate
December 19, 2025

AstraZeneca Pharma India receives CDSCO approval for breast cancer drug

Dato-DXd is a specifically engineered antibody drug conjugate that targets TROP2, a protein frequently overexpressed in breast cancer AstraZeneca Pharma India announced that the Central Drugs Standard Control Organisation (CDSCO) has granted regulatory approval to import, sell, and distribute Datopotamab Deruxtecan (Dato-DXd) in India. The approval reflects AstraZeneca’s focus on bringing to life-changing medicines at […]
Article by: IMT News Desk
Novo Nordisk launches Ozempic in India
Corporate
December 12, 2025

Novo Nordisk launches Ozempic in India

Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living with uncontrolled type 2 diabetes mellitus Novo Nordisk announced the launch of Ozempic (injectable semaglutide) in India. Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living […]
Article by: IMT News Desk